New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareThymosin Alpha-1 vs Pancragen

Thymosin Alpha-1 vs Pancragen

Side-by-side comparison of key properties, dosing, and research.

Immune SupportAnti-Aging & Longevity
Thymosin Alpha-1
Anti-Aging & Longevity
Pancragen
Summary
Thymosin Alpha-1 is a naturally occurring 28-amino acid peptide derived from the thymus gland. It is a powerful immune modulator approved in many countries for treating chronic hepatitis B, hepatitis C, and as an adjunct in cancer immunotherapy.
Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
Half-Life
2–3 hours
Short (minutes); sustained gene-regulatory effects
Admin Route
SubQ
SubQ, Oral
Research
Typical Dose
0.8–1.6 mg
10 mg per day
Frequency
Twice weekly
Daily for 10–30 days
Key Benefits
  • Enhances T-cell and NK cell activity
  • Supports recovery from viral and bacterial infections
  • May reduce inflammation systemically
  • Supports healthy aging and immune resilience
  • Improves vaccine response
  • Supports liver health
  • May help with chronic fatigue syndrome and post-viral conditions
  • Approved in multiple countries for hepatitis B and C treatment
  • Supports pancreatic beta cell function and insulin secretion
  • May improve glucose metabolism in early metabolic dysfunction
  • Protective effects on exocrine pancreatic tissue
  • Anti-aging effects on pancreatic cells
  • Potential support in type 2 diabetes management alongside standard care
  • Reduces pancreatic cellular apoptosis from metabolic stress
  • Complementary to GLP-1 agonists in metabolic protocols
Side Effects
  • Injection site irritation
  • Mild flu-like symptoms initially (immune activation)
  • Fatigue (rare)
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hypoglycemic events reported at standard doses as monotherapy
Stacks With